To Assess Allisartan Isoproxil/Sustained-Release Indapamide in Patients With Essential Hypertension Uncontrolled With Allisartan Isoproxil

NCT06500689 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

366

Enrollment

INDUSTRY

Sponsor class

Conditions

Essential Hypertension

Interventions

DRUG: Allisartan Isoproxil/Sustained-Release Indapamide
DRUG: Allisartan Isoproxil

Sponsor

Shenzhen Salubris Pharmaceuticals Co., Ltd.